BRAND NAMES
- Genurin: Venezuela, China, Italy, Singapore, Taiwan, Vietnam
- Bladuril: Dominican Republic, Argentina, Mexico, Chile, Ecuador, Peru
- Urispas: Lebanon, Oman, Netherlands, France, Belgium, Netherlands, Malta, U.K., Ireland, Lithuania, Malaysia, Singapore, South Africa
 MECHANISM OF ACTION
Flavoxate is a competitive muscarinic receptor antagonist. It is a flavone derivative that exerts an antispasmodic action on the smooth muscle of the urogenital system.
Muscarinic receptors play a role in contractions of urinary bladder smooth muscle and stimulation of salivary secretion. By preventing the binding of acetylcholine to these receptors, Flavoxate reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of micturition, urgency and incontinence episodes.
- For symptomatic relief of : dysuria (painful urination), urgency, nocturia, suprapubic pain, frequency and incontinence during or following affections of the bladder and prostate such as cystitis, cystalgia, prostatitis. urethritis. urethrocystitis. urethrotrigonitis and benign prostatic hypertrophy.
- As an adjuvant in the antispasmodic treatment of calculi of the kidney and ureter, urinary spastic disorders caused by catheterization and cystoscopy. and the sequelae of surgery on the lower urinary tract.
- For the relief of spastic states in the female genital tract such as: Pelvic algias, dysmenorrhea, uterine hypertonia and dyskinesia.
Adults: One 200mg tablet three or four times a day, at regular intervals, preferably afler meals.
In patients with concomitant infections of the urogenital tract. flavoxate should be administered in combination with appropriate anti-infective therapy.
- Known hypersensitivity to Flavoxate.
- Pyloric or duodenal obstruction
- Achalasia (difficulty swallowing)
- Obstructive ileus or intestinal lesions
- Gastrointestinal hemorrhage.
 WARNINGS AND PRECAUTIONS
- Controlled Narrow-Angle Glaucoma: Use with caution in patients being treated for narrow-angle glaucoma
- Urinary Retention: Administer with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
- Central Nervous System Effects: Possible side-effects, are drowsiness, blurred vision, and vertigo. Advise patients not to drive or operate heavy machinery until they know how Flavoxate affects them.
 PREGNANCY AND LACTATION
- Animal studies have shown that the drug has no adverse effects on pregnancy and the fetus. However, as with any other drug, caution in its use is recommended in case of pregnancy, especially during the first three months.
 SIDE EFFECTS
Adverse effects have rarely been reported and include: nausea and vomiting (which usually do not occur when the drug is taken on a full stomach), dryness of mouth. vertigo, headache, drowsiness (which usually disappears when doses are reduced or given at wide intervals), emotional instability, visual and accommodation disturbances, increased ocular tension, urticaria and other dermatoses, mental confusion especially in the elderly patient, dysuria, tachycardia, fever, eosinophilia, and, at high doses constipation.